SuperworthSight Sciences SGHT
- Market cap
- $495.2M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 5.9×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $83.4M
- +9% on a year ago
- Net margin
- −35.7%
- Free cash flow yield
- −4.7%
Sight Sciences trades at 5.9× sales. Its trailing earnings are negative, so it has no PE. Revenue was $83.4M over the last twelve months, up 9% on a year earlier with a −36% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $20M+7% | $18.8M−9% | $19.3M+2% | $21.4M−9% | $20.2M+1% | $19.1M+2% | $17.5M−9% | $19.6M−9% | $19.9M−1% | $20.4M+7% | $19.7M+13% | $23.4M+20% | |
| Cost of revenue | $2.7M−9% | $2.8M−24% | $2.8M−8% | $3M−11% | $3.3M+21% | $2.5M−10% | $2.4M−14% | $3M−2% | $2.7M−17% | $2.6M+3% | $2.7M+13% | $2M−32% |
| Gross profit | $17.3M+10% | $16M−5% | $16.5M+4% | $18.3M−9% | $16.9M−3% | $16.6M+4% | $15.1M−8% | $16.6M−10% | $17.2M+2% | $17.8M+7% | $17M+13% | $21.4M+29% |
| R&D | $4.2M−30% | $3.4M−35% | $4.6M−1% | $4.3M−17% | $4.7M+12% | $4.3M+25% | $4.4M−4% | $4.4M+2% | $3.4M−29% | $2.4M−43% | $2.5M−43% | $2.5M−43% |
| SG&A | $26.5M−16% | $23.7M−18% | $26.6M−7% | $26.7M−11% | $23.4M−12% | $24.2M+2% | $24.5M−8% | $23.9M−11% | $21.8M−7% | $19M−21% | $26.8M+10% | $22.8M−5% |
| −$13.4M−39% | −$11.1M−35% | −$14.7M−16% | −$12.7M−17% | −$11.2M−16% | −$11.9M+7% | −$13.9M−6% | −$11.7M−8% | −$7.9M−30% | −$3.7M−69% | −$12.4M−10% | −$3.9M−67% | |
| Interest expense | $1.4M+27% | $1.4M+11% | $1.2M−6% | $1.1M−15% | $1.2M−20% | $1.2M−14% | $1.3M+5% | $1.3M+12% | $1.3M+14% | $1.3M+11% | $1.3M+0% | $1.3M+1% |
| Pre-tax income | −$13M−42% | −$10.7M−37% | −$16.2M−5% | −$12.3M−17% | −$10.9M−16% | −$11.8M+11% | −$14.1M−13% | −$11.9M−3% | −$8.2M−24% | −$4.2M−65% | −$13M−8% | −$4.4M−63% |
| $78K+311% | $10K+0% | $17K+21% | $15K+88% | $166K+113% | $38K+280% | $41K+141% | $40K+167% | −$79K | $8K−79% | $11K−73% | $28K−30% | |
| Net income | −$13M−41% | −$10.7M−37% | −$16.3M−5% | −$12.3M−16% | −$11.1M−15% | −$11.8M+11% | −$14.2M−13% | −$11.9M−3% | −$8.2M−26% | −$4.2M−65% | −$13M−8% | −$4.4M−63% |
| −$0.27−41% | −$0.22−37% | −$0.33−6% | −$0.25−17% | −$0.22−19% | −$0.23+5% | −$0.28−15% | −$0.23−8% | −$0.16−27% | −$0.08−65% | −$0.24−14% | −$0.08−65% | |
| 48.7M+2% | 48.9M+1% | 49.5M+2% | 49.9M+3% | 50.3M+3% | 50.8M+4% | 51.3M+4% | 51.8M+4% | 52.4M+4% | 53.1M+5% | 53.9M+5% | 54.5M+5% |
Revenue: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
R&D: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
SG&A: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Operating income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Income tax: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Net income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
EPS, diluted: 8 periods, Q1 FY20 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY20: share-days: the 6-month average less the second quarter's. 6 periods, Q4 FY20 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Sight Sciences' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| SGHTSight Sciences | $495.2M | n/m | n/a | 5.9× | +9% | −35.7% | |
| TCMDTactile Systems Technology | $535.5M | 21.9× | 62.9× | 1.5× | +17% | 7.1% | |
| MDXGMimedx | $569.9M | 97.8× | 21.1× | 1.6× | −2% | 1.8% | |
| EMBCEmbecta | $380.2M | 4.6× | 11.7× | 0.4× | −8% | 8.6% | |
| MOVMovado | $701.9M | 17.5× | 13.3× | 1.0× | +5% | 6.0% | |
| INFUInfuSystem | $277.6M | 34.0× | 43.5× | 1.9× | +2% | 6.0% | |
| UTMDUtah Medical Products | $236.3M | 22.6× | 20.9× | 6.5× | −7% | 29.0% | |
| IRMDIradimed | $1.1B | 47.9× | 41.4× | 12.7× | +11% | 26.7% | |
| STAAStaar Surgical | $1.1B | 323× | 143× | 3.3× | +51% | 1.1% | |
| PDEXPro DEX | $199.3M | 15.1× | 16.6× | 2.6× | +16% | 17.6% | |
| BVSBioventus | $1.3B | 19.4× | 27.2× | 2.2× | +3% | 9.4% | |
| Peer median | $552.7M | 22.3× | 24.1× | 2.0× | +4% | 7.8% |
More on Sight Sciences
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .